Injunctions and undertakings in pharma patent fights: the cost of doing business?

When a pharma patentee obtains interlocutory injunctive relief and gives the "usual undertaking as to damages" to the Court but is unsuccessful at the final hearing and the interlocutory injunction is dissolved, the patentee is now at an increased risk of a claim being made for compensation by the Commonwealth.